BioMérieux
In Brief This Week: MLA Diagnostics, BC Platforms, Oncocyte, Biological Dynamics, Devyser, More
News items for the week of Dec. 4, 2023
BioMérieux Q3 Revenues Dip Slightly
The firm confirmed its full-year guidance for organic sales growth of between 4 percent and 6 percent.
The firm said it is actively forging partnerships in the clinical and applied industrial markets to drive adoption of its nanopore sequencing products.
Oxford Nanopore Nabs £70M Investment From BioMérieux, Signs Clinical Collaboration With Mayo Clinic
The investment comes after Oxford Nanopore and BioMérieux's collaboration agreement earlier this year for the development of infectious disease diagnostics.
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
The order-dependent contract is for maintenance and support of a version of the BioFire FilmArray 2.0 molecular diagnostic instrument through January 2029.
Sep 1, 2023
BioMérieux Q2 Revenues Rise 5 Percent
Apr 27, 2023
BioMérieux Q1 Revenues Rise 8 Percent
Feb 16, 2023
Oct 26, 2022